指南与共识消化、代谢与肾脏急症儿科与产科急症

儿童Graves病诊治指南

Graves' disease in children.
指南 / 共识 · Ann Endocrinol (Paris) · 2018-08-16
一句话结论儿童Graves病诊断依据TSH抑制和抗TSH受体抗体阳性,治疗首选咪唑类抗甲状腺药物,初始剂量0.4-0.8mg/kg/天(甲巯咪唑0.3-0.6mg/kg/天),最大30mg,疗程3-6年,丙硫氧嘧啶禁忌。

该指南由法国内分泌学会发布,针对儿童Graves病的诊断和治疗提出推荐。诊断基于血清TSH浓度抑制和抗TSH受体抗体阳性,甲状腺超声和核素扫描非必需。治疗首选咪唑类抗甲状腺药物(卡比马唑或甲巯咪唑),初始剂量0.4-0.8mg/kg/天(甲巯咪唑0.3-0.6mg/kg/天),最大30mg,疗程3-6年,预期约50%患者缓解。丙硫氧嘧啶禁忌。治疗前需查血常规和转氨酶,随访中不常规监测血常规,但发热或咽痛时应急查血常规,中性粒细胞<1000/mm³时停药或减量。

要点

  • 诊断儿童Graves病依据TSH抑制和抗TSH受体抗体阳性,甲状腺超声和核素扫描非必需。
  • 治疗首选咪唑类抗甲状腺药物(卡比马唑或甲巯咪唑),初始剂量0.4-0.8mg/kg/天(甲巯咪唑0.3-0.6mg/kg/天),最大30mg。
  • 丙硫氧嘧啶禁忌用于儿童Graves病。
  • 治疗前查血常规评估中性粒细胞,随访不常规查血常规,但发热或咽痛时应急查;中性粒细胞<1000/mm³时停药或减量,<500且持续时可能永久禁忌。
  • 初始治疗疗程3-6年,预期约50%患者缓解,需告知家庭可能需根治治疗。

适用人群与场景

  • 儿童Graves病患者
  • 适用于儿科内分泌专科诊治

诊断标准与关键阈值

  • 诊断依据:血清TSH浓度抑制和抗TSH受体抗体阳性(推荐等级1/+++)。
  • 甲状腺超声非诊断必需,可用于评估甲状腺肿大小和均匀性(推荐等级2/+)。
  • 甲状腺核素扫描非诊断必需(推荐等级1/+++)。
  • T4L和T3L测定非诊断必需,但可用于管理和预后评估(推荐等级1/++)。
  • 无TSH受体自身抗体时,需考虑遗传性甲状腺功能亢进症(推荐等级1/++)。

处置流程与药物剂量

  • 药物治疗为儿童一线治疗,使用咪唑类(卡比马唑或甲巯咪唑),初始剂量0.4-0.8mg/kg/天(甲巯咪唑0.3-0.6mg/kg/天),根据初始严重程度,最大30mg(推荐等级1/++)。
  • 丙硫氧嘧啶禁忌用于儿童Graves病(推荐等级1/+++)。
  • 治疗前可查血常规评估甲状腺功能亢进所致中性粒细胞减少程度(推荐等级2/+);随访中不常规查血常规。
  • 发热或咽痛时应急查血常规;中性粒细胞<1000/mm³时停用或减量合成抗甲状腺药物,严重(<500)且持续中性粒细胞减少时可能永久禁忌;否则可恢复治疗(推荐等级1/++)。
  • 治疗前应测转氨酶(推荐等级2/+);肝功能系统监测未获共识验证。
  • 出现黄疸、消化系统症状或瘙痒时,应测肝酶(AST、ALT)、总胆红素和结合胆红素及碱性磷酸酶(推荐等级1/++)。
  • 初始治疗疗程3至6年,取决于年龄、诊断时疾病严重程度和抗TSH受体抗体持续性。
  • 应向家庭和儿童解释药物治疗预期成功率(治疗数年后50%患者缓解)及失败或不耐受时可能需要根治治疗(推荐等级1/++)。

红旗征与不能漏的情况

  • 发热或咽痛:应急查血常规;中性粒细胞<1000/mm³时停用或减量抗甲状腺药物,<500且持续时可能永久禁忌。
  • 黄疸、消化系统症状或瘙痒:应测肝酶(AST、ALT)、总胆红素和结合胆红素及碱性磷酸酶。

研究设计与关键结果

  • 制定机构:法国内分泌学会(Ann Endocrinol (Paris));方法:基于证据分级(1/+++至2/+)的推荐。

证据类型、等级与局限

  • 证据类型:指南;推荐等级采用1/+++、1/++、2/+、1/+等级别;局限:原文未报告局限性。

对床旁实践的改变

  • 儿童Graves病诊断无需常规甲状腺超声和核素扫描,依据TSH抑制和抗TSH受体抗体阳性即可。
  • 丙硫氧嘧啶禁忌用于儿童,应选用咪唑类(卡比马唑或甲巯咪唑)。
  • 治疗前查血常规和转氨酶,随访不常规查血常规,但发热或咽痛时应急查。
  • 初始治疗疗程3-6年,需向家庭解释约50%缓解率及根治治疗可能性。
  • 根治治疗指征包括:抗甲状腺药物禁忌、因依从性差导致甲状腺功能亢进控制不佳、长期药物治疗后复发、家庭和儿童因个人原因要求(推荐等级1/+)。
  • 手术为5岁以下儿童或巨大、结节性、压迫性甲状腺肿的根治方法(推荐等级2/++)。
  • 当有根治治疗指征时,5岁后(更常在青春期后)可讨论I-131治疗,需甲状腺肿不那么大(推荐等级1/++)。
  • 女性患者应在计划妊娠前、妊娠开始和妊娠期间由内分泌科医生评估,即使缓解或已根治。

指南或共识出处

  • 指南名称:Graves' disease in children;发布机构:法国内分泌学会(Ann Endocrinol (Paris));年份:原文未写明。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

R1 The diagnosis of Graves' disease in children is based on detecting a suppression of serum TSH concentrations and the presence of anti-TSH receptor antibodies. 1/+++. R2 Thyroid ultrasound is unnecessary for diagnosis, but can be useful for assessing the size and homogeneity of the goiter. 2/+. R3. Thyroid scintigraphy is not required for the diagnosis of Graves' disease. 1/+++. R4. The measurement of T4L and T3L levels is not necessary for the diagnosis of Graves' disease in children but can be useful for the management and assessment of prognosis. 1/++. R5. In the absence of TSH receptor autoantibodies, the possibility of genetically inherited hyperthyroidism must be considered. 1/++. R6. Drug therapy is the primary line of treatment for children and consists of imidazole, carbimazole or thiamazole, with an initial dosage of 0.4 to 0.8mg/kg/day (0.3 to 0.6mg/kg/day for thiamazole) depending on the initial severity, up to maximum of 30mg. 1/++. R7. Propylthiouracil is contraindicated for children with Grave's disease. 1/+++. R8. Before starting treatment, it may be useful to perform a CBC in order to assess the degree of neutropenia caused by hyperthyroidism. It is not necessary to perform systematic CBCs during follow-up. 2/+. R9. An emergency CBC should be performed if symptoms include fever or angina. If neutrophil counts are <1000/mm3, synthetic antithyroid therapy should be discontinued or decreased and may be permanently contraindicated in severe (<500) and persistent neutropenia. Otherwise treatment may be resumed. 1/++. R10. Transaminases levels should be measured before initiating treatment. Systematic monitoring of liver function is not consensually validated. 2/+. R11. In cases of jaundice, digestive disorders or pruritus, measuring liver enzymes (AST, ALT), total and conjugated bilirubin and alkaline phosphatases is indicated. 1/++. R12. Patients and parents should be informed of the possible side effects of antithyroid agents. 1/+. R13. Therapeutic education of parents and children is important in ensuring the best possible treatment compliance. 2/++. R14. Given the specificities involved in the treatment of Graves' disease in children, medical care should be provided by a specialist accustomed to treating endocrinopathies in pediatric patients. 2/+. R15. Depending on patient age, the severity of the disease at diagnosis and the persistence of anti-TSH receptor antibodies, the initial course of treatment must take place over an extended period of 3 to 6 years. R16.The anticipated success rates of medical treatment (50% of patients in remission following several years of treatment) should be explained to the family and the child. The possibility that radical treatment may be required in case of failure or intolerance of medical treatment should also be discussed. 1/++. R17.In females with Graves' disease, it is important to explain that they must undergo an assessment by an endocrinologist before planning future pregnancies, from the start of pregnancy and during the course of pregnancy. This is true in all female patients, even those in remission after medical treatment, or those who have undergone radical treatment. R18.Indications for a radical treatment can arise in cases of: 1/+: contraindication to antithyroid agents; poorly controlled hyperthyroidism due to lack of compliance; relapse despite prolonged medical treatment; a request made by the family and child for personal reasons. R19.Surgery is the radical method of treatment used in children under 5 years of age, or in cases of very large, nodular, or compressive goiters. 2/++. R20. The surgeon's experience in dealing with thyroidectomies in children is likely to be the most significant determining factor in limiting the morbidity of the procedure (alongside any collaboration between a pediatric surgeon and an adult surgeon). 1/++. R21 When radical treatment is indicated, I-131 treatment may be discussed after 5 years (but more often after puberty), if the goiter is not too large. Experience from monitoring Graves' disease in North American children is reassuring. 1/++.

来源:Ann Endocrinol (Paris),查看原文。版权归原作者所有。

参考来源

  1. Léger J, Oliver I, Rodrigue D, et al. Graves' disease in children. Ann Endocrinol (Paris). 2018. PMID: 30180972. doi:10.1016/j.ando.2018.08.001

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。